Guillain-Barre Syndrome (GBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Guillain-Barre Syndrome (GBS) Market Outlook

Thelansis’s “Guillain-Barre Syndrome (GBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Guillain-Barre Syndrome (GBS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Guillain-Barre Syndrome (GBS) Overview

Guillain-Barre Syndrome (GBS) is a type of acute paralytic neuropathy that is both common and severe. Typically involves progressive limb weakness accompanied by decreased or absent reflexes. However, some patients experience localized weakness or other symptoms, such as facial diplegia or paraesthesia. GBS is also associated with several other disorders, such as Miller-Fisher syndrome and Bickerstaff brainstem encephalitis. These conditions can share similar biomarkers but present with different clinical features. GBS can be broadly classified into two types: acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), based on the site of the target antigen. The underlying mechanisms of GBS involve both innate and adaptive immunity. Innate immunity is associated with dendritic cells, complement fractions, mast cells, and specific toll-like receptors. Adaptive immunity is characterized by IL17 and IL22 secretion, anomalies in CD4(+)CD25(+) regulator T-cells, and anti-ganglioside and anti-nodes of Ranvier protein IgG. GBS is triggered by various factors, including infections by viruses such as dengue, hepatitis E, and Zika, as well as cross-reactivity phenomena in cases of Campylobacter jejuni diarrhea. Factors that affect prognosis include older age, rapid disease progression, diarrhea as a triggering factor, and the need for mechanical ventilation. Clinical scores such as EGRIS can be used to assess the short-term risk of intubation, and the EGOS and mEGOS can be used to determine the capacity to walk at six months or four weeks, respectively.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Guillain-Barre Syndrome (GBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment

Popular posts from this blog

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more

Chondrosarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Image
  Chondrosarcoma is a rare malignant tumor that forms a cartilaginous matrix. Chondrosarcomas arising de novo are termed primary chondrosarcomas, while those developing in pre-existing benign cartilaginous tumors such as osteochondroma or enchondroma are referred to as secondary chondrosarcomas. CHS constitutes various groups of malignant bone tumors and encompasses multiple histological subtypes. Overall, conventional CHS is the most common subtype. It accounts for 85% of CHS, followed by dedifferentiated (10%), mesenchymal and clear cell CHS, these two representing less than 2% of all CHS cases. Conventional CHS can develop de novo or in a pre-existing enchondroma and osteochondroma. CHS is classified into three grades based on cellular atypia, mitotic figures, and cellularity. CHS grades 1 and 2 are represented by 85% of all CHSs, 15% of cases are grade 3, and the dedifferentiated CHS. According to the latest WHO recommendations, CHS should be classified into central or secondar...
Read more

Nocturia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Nocturia is a condition where an individual wakes up more than once during the night to urinate. It is divided into two main categories: upper urinary tract and lower urinary tract dysfunction. Nocturia is often associated with lower urinary tract symptoms (LUTS), such as benign prostatic obstruction (BPO) and overactive bladder (OAB). However, it can also be caused by nighttime urine overproduction or nocturnal polyuria (NP), resulting from renal, cardiovascular, or pulmonary factors. Nocturia is multifactorial and can be caused by one of four main problems: Nocturnal polyuria Global polyuria Bladder functional storage issues Sleep disorders Hormonal problems are primarily responsible for nocturnal and global polyuria. The management of nocturia requires multidisciplinary care, and treatment involves behavioral interventions and medications, including anticholinergics. It affects 50 million people in the United States, with 10 million diagnosed with nocturia but onl...
Read more